These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 26293208)

  • 1. Coma associated with nelarabine in an elderly patient with T-cell acute lymphoblastic leukemia and severe chronic renal disease.
    Nishijima TF; Shea TC; Wood WA; Voorhees PM; Jamieson K
    Leuk Lymphoma; 2016; 57(4):957-60. PubMed ID: 26293208
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia: literature review and own experience.
    Dyakonova YY; Bydanov OI; Popov AM; Olshanskaya YV; Boichenko EG; Aleynikova OV; Maschan MA; Shelikhova LN; Litvinov DV; Khachatryan LA; Ponomareva NI; Fechina LG; Novichkova GA; Pashanov ED; Karachunskiy AI
    Ter Arkh; 2018 Aug; 90(7):38-50. PubMed ID: 30701921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pediatric T-ALL complicated by irreversible nelarabine neurotoxicity.
    Kanayama T; Imamura T; Nakagawa N; Osone S; Hosoi H
    Pediatr Int; 2017 Jul; 59(7):843-845. PubMed ID: 28745456
    [No Abstract]   [Full Text] [Related]  

  • 4. Nelarabine-related rhabdomyolysis in a patient with T-cell acute lymphoblastic leukemia.
    Pandey RK; DiPippo A; Kadia T; Pemmaraju N; Workeneh BT; Jabbour E; Ravandi F; Jain N
    Leuk Lymphoma; 2020 Nov; 61(11):2775-2777. PubMed ID: 32654562
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety of nelarabine in adults with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma.
    Candoni A; Lazzarotto D; Petruzzellis G
    Expert Opin Drug Saf; 2021 Jul; 20(7):751-756. PubMed ID: 33866913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient.
    Papayannidis C; Iacobucci I; Abbenante MC; Curti A; Paolini S; Parisi S; Baccarani M; Martinelli G
    Am J Hematol; 2010 Aug; 85(8):608. PubMed ID: 20658590
    [No Abstract]   [Full Text] [Related]  

  • 7. Management of Nelarabine induced neurotoxicity in a child with T-cell acute lymphoblastic lymphoma.
    Karthik U; Motwani J
    J Oncol Pharm Pract; 2024 Apr; 30(3):594-596. PubMed ID: 38105625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fatal neurological side-effects with necrosis of spinal cord following nelarabine treatment in a child with relapsed T-cell acute lymphoblastic leukemia.
    Hartz B; Löbel U; Hagel C; Escherich G
    Am J Hematol; 2013 Dec; 88(12):1096-7. PubMed ID: 23873785
    [No Abstract]   [Full Text] [Related]  

  • 9. Nelarabine (Arranon) for T-cell acute lymphoblastic leukemia.
    Med Lett Drugs Ther; 2006 Feb; 48(1228):14-5. PubMed ID: 16467734
    [No Abstract]   [Full Text] [Related]  

  • 10. Severe, reversible nelarabine-induced neuropathy and myelopathy.
    Alberti P; Parma M; Pioltelli P; Pogliani EM; Terruzzi E; Stasia A; Doni E; Cecchetti C; Cavaletti G
    J Peripher Nerv Syst; 2016 Sep; 21(3):154-6. PubMed ID: 27117493
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study.
    Zwaan CM; Kowalczyk J; Schmitt C; Bielorai B; Russo MW; Woessner M; Ranganathan S; Leverger G
    Br J Haematol; 2017 Oct; 179(2):284-293. PubMed ID: 28771663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nelarabine, cyclosphosphamide and etoposide for adults with relapsed T-cell acute lymphoblastic leukaemia and lymphoma.
    Luskin MR; Ganetsky A; Landsburg DJ; Loren AW; Porter DL; Nasta SD; Svoboda J; Luger SM; Frey NV
    Br J Haematol; 2016 Jul; 174(2):332-4. PubMed ID: 26403537
    [No Abstract]   [Full Text] [Related]  

  • 13. The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience.
    Jain P; Kantarjian H; Ravandi F; Thomas D; O'Brien S; Kadia T; Burger J; Borthakur G; Daver N; Jabbour E; Konopleva M; Cortes J; Pemmaraju N; Kelly MA; Cardenas-Turanzas M; Garris R; Faderl S
    Leukemia; 2014 Apr; 28(4):973-5. PubMed ID: 24157581
    [No Abstract]   [Full Text] [Related]  

  • 14. Nelarabine for T cell acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation: an opportunity to improve survival.
    Forcade E; Leguay T; Vey N; Baruchel A; Delaunay J; Robin M; Socié G; Dombret H; Peffault de Latour R; Raffoux E
    Biol Blood Marrow Transplant; 2013 Jul; 19(7):1124-6. PubMed ID: 23648236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
    DeAngelo DJ
    Hematol Oncol Clin North Am; 2009 Oct; 23(5):1121-35, vii-viii. PubMed ID: 19825456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation.
    Gökbuget N; Basara N; Baurmann H; Beck J; Brüggemann M; Diedrich H; Güldenzoph B; Hartung G; Horst HA; Hüttmann A; Kobbe G; Naumann R; Ratei R; Reichle A; Serve H; Stelljes M; Viardot A; Wattad M; Hoelzer D
    Blood; 2011 Sep; 118(13):3504-11. PubMed ID: 21715318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nelarabine.
    Sanford M; Lyseng-Williamson KA
    Drugs; 2008; 68(4):439-47. PubMed ID: 18318562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia.
    Homminga I; Zwaan CM; Manz CY; Parker C; Bantia S; Smits WK; Higginbotham F; Pieters R; Meijerink JP
    Blood; 2011 Aug; 118(8):2184-90. PubMed ID: 21730354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nelarabine-associated myelopathy in a patient with acute lymphoblastic leukaemia: Case report.
    Amer-Salas N; González-Morcillo G; Rodríguez-Camacho JM; Cladera-Serra A
    J Oncol Pharm Pract; 2021 Jan; 27(1):244-249. PubMed ID: 32517638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.
    Lonetti A; Cappellini A; Bertaina A; Locatelli F; Pession A; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; Zambonin L; Neri LM; Martelli AM; Chiarini F
    J Hematol Oncol; 2016 Oct; 9(1):114. PubMed ID: 27776559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.